The benefits of anti-VEGF therapy in patients with metastatic colorectal cancer have been reported by several trials and studies, with the median overall survival increasing from 1.4 to 4.7 months and progression-free survival increasing from 1.4 to 4.5 months [12,13,14,15,16]. This evidence concerns the gene VEGFA and metastatic colorectal cancer.